Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Listed as NCT00159770, this PHASE3 trial focuses on Psychotic Disorders and Schizoaffective Disorder and remains completed. Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., it has been updated 8 times since 2001, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark, Arhus C, Denmark, Augustenborg, Denmark, Ballerup Municipality, Denmark, Basel, Switzerland, Bern, Switzerland, Brovst, Denmark, Bulle, Switzerland, Chêne-Bourg, Switzerland, Copenhagen, Denmark and 33 more location s